CliffBio
biologic

Sevenfact

coagulation factor VIIa (recombinant)-jncw

Loss of exclusivityJune 2036projected — 12-year biologic exclusivity estimate
CompanyLaboratoire Francais du Fractionnement et des Biotechnologies S.A.

Drug detail

Brand nameSevenfact
Active ingredientcoagulation factor VIIa (recombinant)-jncw
Strength2MG
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalJune 2024
Marketing statusRx

More from Laboratoire Francais du Fractionnement et des Biotechnologies S.A.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Sevenfact patent cliff — loss of exclusivity June 2036 | CliffBio